ArticleClinical kidney journal2024
Cost-effectiveness of screening for chronic kidney disease: existing evidence and knowledge gaps.
Article in Clinical kidney journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- The updated global burden of chronic kidney disease: one death every 20 seconds.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
- Article
- Renal Risk Medication Quick Guide to Aid Pharmacist-Led Medication Review in Frail Hospitalized Geriatric Patients: A Multicenter Exploratory Study.Healthcare (Basel, Switzerland) · 2026Article
- The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict diabetic kidney disease development and progression: evidence from two nationwide cohorts and a biopsy-proven clinical cohort.Cardiovascular diabetology · 2026Article
- Artificial intelligence-based quantification of retinal microvascular biomarkers from fundus photography of chronic kidney disease: a case-control study.Frontiers in medicine · 2026Article
- A Pilot Study of Opportunistic Chronic Kidney Disease Screening in Primary Care Using a Clinical Decision Support System.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Chronic kidney disease in Romania: national adjusted prevalence, risk factors, and temporal trends in high-risk groups.BMC nephrology · 2025Article
- Impact of albuminuria screening in primary care on the detection and management of chronic kidney disease: findings from the ONDAAS study.Clinical kidney journal · 2025Article
- Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study.The Lancet regional health. Western Pacific · 2025Article
- Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study.BMC primary care · 2025Observational
- A Predictive Nomogram for Selective Screening of Chronic Kidney Disease: A Population-Based Study.Canadian journal of kidney health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well known that the worldwide prevalence of chronic kidney disease (CKD) has risen to over 10% of the general population during the past decades. Patients with CKD are at increased risk of both kidney failure and cardiovascular disease (CVD), posing a substantial health challenge. Therefore, screening for CKD is warranted to identify and treat patients early to prevent progression and complications. In this issue of the Journal, Yeo and colleagues provide an updated systematic review of the cost-effectiveness of screening for CKD in the general adult population. They show that screening for CKD in high-risk populations is cost-effective and that there is limited evidence for screening the general population. It should be noted that most studies they discuss do not consider the benefit of screening to prevent CVD in addition to preventing kidney failure, the treatment effect of novel therapeutic agents such as SGLT2 inhibitors, and the possibility of screening in a home-based setting. These three aspects will likely improve the cost-effectiveness of CKD screening, making it feasible to move towards general population screening for CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.